Back to AZN Stock Lookup
Pages: 1 2 »» Last Page

AZN – Analyst Comments

Apr 22, 2014 10:38 AM Deals, Deals, Deals in Pharmaceutical Sector; Who's Next?
Apr 22, 2014 08:44 AM Pharma M&A May be Entering Megadeals Phase, Says Goldman Sachs Analyst (AGN) (VRX) (PFE) (AZN) (ACT) (FRX)
Apr 21, 2014 09:13 AM Pfizer (PFE)/AstraZeneca (AZN) Potential Combo Likely Has Synergies, Says Goldman Sachs Analyst
Jan 9, 2014 07:35 AM Jefferies Upgrades AstraZeneca (AZN) to Hold
Oct 11, 2013 07:58 AM Jefferies Downgrades AstraZeneca (AZN) to Underperform
Sep 30, 2013 10:55 AM Clovis Oncology (CLVS) Reiterated Outperform at Leerink Swann as Race with AstraZeneca (AZN) Heats Up
Sep 30, 2013 10:08 AM AstraZeneca (AZN) AZD-9291 Data Highlights Blockbuster Potential
Jun 26, 2013 08:52 AM MannKind (MNKD) Price Target Raised to $8.40 at Piper
Jun 4, 2013 07:58 AM Needham & Company Upbeat on ISIS Pharmaceuticals (ISIS) Following ASCO
Jun 3, 2013 03:34 PM Merck (MRK) Immuno-Oncology Offering Lacks Combo; Goldman Maintains Neutral
May 28, 2013 08:34 AM Jefferies Boosts Price Targets Accross Pharmaceuticals Sector (ABT) (JNJ) (BMY) (more...)
Apr 10, 2013 08:30 AM Jefferies Lifts PT on Pharmaceuticals Stocks (ABBV) (NVS) (SNY) (PFE)
Apr 3, 2013 09:59 AM Dupilumab Could End of Being 'Blockbuster' Asthma Drug - Analyst (SNY) (REGN)
Apr 1, 2013 11:47 AM Amarin's (AMRN) Vascepa Tracking Well 3-Months In; Investors Eye Tier 2 Designation
Sep 12, 2012 09:23 AM Leerink Swann Maintains an 'Outperform' on Teva Pharma (TEVA); Review with Patent Specialist
Aug 20, 2012 11:03 AM Amarin (AMRN) NCE Status Could Happen by September 14 and Takeover Could Follow - MKM
Aug 2, 2012 08:37 AM Nomura Securities Reiterates a 'Reduce' on AstraZeneca (AZN); Overpayment Risk in Deal with Bristol Myers (BMY)
Jul 13, 2012 08:32 AM Jefferies on Pharmaceuticals: Global Pharmaceuticals Q2'12 Earnings Preview; Where is it Safe to Hide?
Jul 2, 2012 03:10 PM Barclays on AstraZeneca (AZN): Acquisition of AMLN Makes Strategic Sense but High Price Tag
Jun 5, 2012 07:38 AM Jefferies Discusses Array BioPharma (ARRY) After Detailed Selumetinib Ph2 Data in NSCLC
May 1, 2012 02:39 PM Cantor Fitzgerald Maintains a 'Buy' on Warner Chilcott (WCRX); Let's Make It Official
Mar 28, 2012 12:35 PM Analysts Expecting Higher Bids for Amylin (AMLN)
Feb 2, 2012 08:53 AM Canaccord Genuity Reiterates a 'Buy' on Impax Labs (IPXL); Raising Estimates on Deal Announcement; Sentiment Starting to Shift
Feb 2, 2012 08:06 AM Needham & Company on Impax Labs (IPXL): Not a Strategic Game-Change but Zomig Offsets SG&A Ramp and Provides Short-Term EPS Boost
Jan 6, 2012 10:58 AM Needham & Company Maintains a 'Hold' on Targacept (TRGT); Sidelined Until TC5214 Phase 3 Story in Depression is Fully Resolved
Oct 19, 2011 12:14 PM Jefferies on Abbott (ABT) Split: Pharma Unit Could Be Worth $29/Share, Medical Unit $32/Share
Sep 22, 2011 03:10 PM Needham & Company Maintains a 'Buy' on Targacept (TRGT); Expect Continued Positive Results from AZN Collaboration
Jul 13, 2011 01:11 PM Barclays on U.S. Diagnostics: FDA Issues draft guidance on companion diagnostics; Positive read for QGEN
Jul 12, 2011 01:57 PM Barclays on U.S. Retail Hardlines: - Initial Take/Pricing Study on New Pet Supply E-commerce Site
Jun 20, 2011 10:20 AM Eli Lilly (LLY) Might Be M&A Target if Things Don't Shape Up
May 16, 2011 02:05 PM Global Pharmaceuticals: Global Therapeutic Conference 2011: Focus on Real-World Medicine
May 6, 2011 08:57 AM UPDATE - Needham & Company Upgraded Targacept (TRGT) to Strong Buy; Valuation Attractive after Distraction of AstraZeneca TC-5619 Option Decision
Mar 10, 2011 07:59 AM Jefferies Cuts Price Target on POZEN Inc. (POZN) by 28.5%, Major Patent Risk
Mar 7, 2011 02:16 PM Barclays on Healthcare Services: Weekly Flu Clues Review
Feb 2, 2011 01:20 PM Barclays Reiterates an 'Overweight' on Array BioPharma (ARRY); Reports FY2Q11, Data for MEK inhibitors in 2011
Sep 15, 2010 02:38 PM Leerink Swann Raises Target on Savient (SVNT) to $22; Highlights Takeover Potential Following Krystexxa Approval
Apr 26, 2010 08:41 AM Brean Murray Maintains a 'Buy' on Pozen, Inc. (POZN); Raises PT on Belief in Vimovo's Approval
Dec 7, 2009 03:02 PM Wedbush Maintains an 'Outperform' on Nektar Therapeutics (NKTR), Recent Marketing Trip Focused on Upcoming Ovarian Cancer Data
Sep 22, 2009 08:43 AM Morgan Joseph Reiterates a 'Buy' on Nektar Technology (NKTR); Sees Substantial Added Value From AstraZeneca Deal
Jul 9, 2009 09:47 AM Natixis Bleichroeder Lifts Price Target on Targacept (TRGT) to $7.50
Jan 8, 2009 11:06 AM Citi Analysts Call 2009 Global Equity Outlook 'Battling The Bear' - Issue Global Preferred List
Apr 21, 2008 10:21 AM Merrill Lynch added AstraZeneca plc (AZN) to its Least Preferred List
Apr 16, 2008 09:39 AM Citi Maintains 'Buy' on POZEN (POZN), Increases Price Target
Mar 18, 2008 08:55 AM Shire plc (SHPGY) Higher On AstraZeneca Takeover Rumors
Feb 15, 2008 08:52 AM Goldman Sachs removed AstraZeneca plc (AZN) from their Conviction Buy list
Nov 9, 2007 10:31 AM Gene Marcial's BusinessWeek's Picks Of The Weeks (GENR, PBR, CWST)
Apr 23, 2007 11:21 AM Rodman & Renshaw Comments on the "Aftershock" of MEDI/AZN Deal
Feb 28, 2006 06:08 PM Jim Cramer mentions NUVO, CATG, and NSTK
Jan 10, 2006 12:02 AM Citigroup Raises its Price Target on AZN
Dec 22, 2005 10:17 AM Analyst Note Revisited After AGIX/AZN Deal
Pages: 1 2 »» Last Page

Back to AZN Stock Lookup